12/4
01:41 pm
srrk
Scholar Rock (SRRK) valuation after FDA manufacturing update and apitegromab resubmission plans [Yahoo! Finance]
Low
Report
Scholar Rock (SRRK) valuation after FDA manufacturing update and apitegromab resubmission plans [Yahoo! Finance]
12/3
03:42 pm
srrk
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/20
06:03 am
srrk
Scholar Rock (NASDAQ:SRRK) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Medium
Report
Scholar Rock (NASDAQ:SRRK) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/18
11:04 am
srrk
Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $47.00. They now have an "overweight" rating on the stock.
Medium
Report
Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $47.00. They now have an "overweight" rating on the stock.
11/18
09:00 am
srrk
Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.
Medium
Report
Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.
11/18
08:00 am
srrk
Scholar Rock to Present at Upcoming Investor Conferences
Medium
Report
Scholar Rock to Present at Upcoming Investor Conferences
11/17
10:23 am
srrk
Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at Barclays PLC from $44.00 to $45.00. They now have an "overweight" rating on the stock.
Low
Report
Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at Barclays PLC from $44.00 to $45.00. They now have an "overweight" rating on the stock.
11/16
11:26 am
srrk
Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses [Yahoo! Finance]
Low
Report
Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses [Yahoo! Finance]
11/15
07:37 am
srrk
Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress [Yahoo! Finance]
Low
Report
Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress [Yahoo! Finance]
11/14
03:06 pm
srrk
Scholar Rock (NASDAQ:SRRK) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Scholar Rock (NASDAQ:SRRK) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
11/14
02:39 pm
srrk
Scholar Rock (SRRK): Exploring Valuation After Recent Company Updates Catch Investor Attention [Yahoo! Finance]
Low
Report
Scholar Rock (SRRK): Exploring Valuation After Recent Company Updates Catch Investor Attention [Yahoo! Finance]
11/14
02:07 pm
srrk
Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/14
02:07 pm
srrk
Scholar Rock outlines 2026 apitegromab launch plan and accelerates supply chain redundancy amid regulatory review [Seeking Alpha]
Low
Report
Scholar Rock outlines 2026 apitegromab launch plan and accelerates supply chain redundancy amid regulatory review [Seeking Alpha]
11/14
07:07 am
srrk
Scholar Rock GAAP EPS of -$0.90 misses by $0.06 [Seeking Alpha]
High
Report
Scholar Rock GAAP EPS of -$0.90 misses by $0.06 [Seeking Alpha]
11/14
07:00 am
srrk
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
High
Report
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/13
10:52 am
srrk
Scholar Rock Q3 2025 Earnings Preview [Seeking Alpha]
Low
Report
Scholar Rock Q3 2025 Earnings Preview [Seeking Alpha]
11/12
04:15 pm
srrk
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/10
11:29 am
srrk
Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating) [Seeking Alpha]
Low
Report
Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating) [Seeking Alpha]
11/4
08:00 am
srrk
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
Low
Report
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
10/23
08:00 am
srrk
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
Low
Report
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
10/20
01:29 pm
srrk
Scholar Rock (NASDAQ:SRRK) had its price target lowered by analysts at Truist Financial Corporation from $54.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
Scholar Rock (NASDAQ:SRRK) had its price target lowered by analysts at Truist Financial Corporation from $54.00 to $44.00. They now have a "buy" rating on the stock.
10/17
04:15 pm
srrk
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/11
08:37 am
srrk
Scholar Rock Holding's Srinivas Akkaraju Acquires 3,707% More Stock [Yahoo! Finance]
High
Report
Scholar Rock Holding's Srinivas Akkaraju Acquires 3,707% More Stock [Yahoo! Finance]
10/9
05:33 pm
srrk
Why Scholar Rock Stock Raced 6% Higher Today [Yahoo! Finance]
Medium
Report
Why Scholar Rock Stock Raced 6% Higher Today [Yahoo! Finance]
10/9
08:07 am
srrk
Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $53.00 price target on the stock.
Medium
Report
Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $53.00 price target on the stock.